Close Menu

This week in the PNAS Early Edition, researchers at the Washington University School of Medicine show that LRP6 silencing in breast cancer cells reduces Wnt signaling, cell proliferation, and tumor growth. Their results suggest that an LRP6 antagonist, Mesd, is a promising antitumor agent and potential therapeutic target for breast cancer subtypes with Wnt activation at the cell surface.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.